Table 1 Correlation analyzed between IGF2BP3 expression and clinicopathologic characteristics in bladder cancer based on TCGA database
Characteristic | Low expression of IGF2BP3 | High expression of IGF2BP3 | p |
|---|---|---|---|
n | 207 | 207 | Â |
Gender, n (%) | Â | Â | 0.045 |
 Female | 45 (10.9%) | 64 (15.5%) |  |
 Male | 162 (39.1%) | 143 (34.5%) |  |
Age, n (%) | Â | Â | 0.372 |
 <  = 70 | 122 (29.5%) | 112 (27.1%) |  |
 > 70 | 85 (20.5%) | 95 (22.9%) |  |
T stage, n (%) | Â | Â | 0.003 |
 T1 | 5 (1.3%) | 0 (0%) |  |
 T2 | 73 (19.2%) | 46 (12.1%) |  |
 T3 | 87 (22.9%) | 109 (28.7%) |  |
 T4 | 30 (7.9%) | 30 (7.9%) |  |
N stage, n (%) | Â | Â | 0.407 |
 N0 | 115 (31.1%) | 124 (33.5%) |  |
 N1 | 25 (6.8%) | 21 (5.7%) |  |
 N2 | 41 (11.1%) | 36 (9.7%) |  |
 N3 | 2 (0.5%) | 6 (1.6%) |  |
M stage, n (%) | Â | Â | 0.535 |
 M0 | 117 (54.9%) | 85 (39.9%) |  |
 M1 | 5 (2.3%) | 6 (2.8%) |  |
Histologic grade, n (%) |  |  |  < 0.001 |
 High Grade | 185 (45%) | 205 (49.9%) |  |
 Low Grade | 21 (5.1%) | 0 (0%) |  |
Lymphovascular invasion, n (%) | Â | Â | 1.000 |
 No | 63 (22.3%) | 67 (23.7%) |  |
 Yes | 74 (26.1%) | 79 (27.9%) |  |